Dicot Pharma AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot Pharma AB (KN0) - Net Assets
Latest net assets as of June 2025: €106.30 Million EUR
Based on the latest financial reports, Dicot Pharma AB (KN0) has net assets worth €106.30 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€118.30 Million) and total liabilities (€12.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €106.30 Million |
| % of Total Assets | 89.86% |
| Annual Growth Rate | 57.91% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 340.36 |
Dicot Pharma AB - Net Assets Trend (2021–2024)
This chart illustrates how Dicot Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dicot Pharma AB (2021–2024)
The table below shows the annual net assets of Dicot Pharma AB from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €111.67 Million | +151.54% |
| 2023-12-31 | €44.39 Million | +728.55% |
| 2022-12-31 | €5.36 Million | -81.10% |
| 2021-12-31 | €28.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dicot Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13360830000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €311.45 Million | 278.91% |
| Total Equity | €111.67 Million | 100.00% |
Dicot Pharma AB Competitors by Market Cap
The table below lists competitors of Dicot Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
365330
KQ:365330
|
$47.65 Million |
|
Diamond Biotechnology Co., Ltd
TWO:6815
|
$47.66 Million |
|
Jalles Machado S/A
SA:JALL3
|
$47.69 Million |
|
Mayfield Group Holdings Ltd
AU:MYG
|
$47.70 Million |
|
Frontier Energy Ltd
AU:FHE
|
$47.63 Million |
|
CATES ELEKTRIK
IS:CATES
|
$47.62 Million |
|
Gaia Inc
NASDAQ:GAIA
|
$47.62 Million |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
$47.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dicot Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 44,393,000 to 111,667,000, a change of 67,274,000 (151.5%).
- Net loss of 57,696,000 reduced equity.
- New share issuances of 124,946,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-57.70 Million | -51.67% |
| Share Issuances | €124.95 Million | +111.89% |
| Other Changes | €24.00K | +0.02% |
| Total Change | €- | 151.54% |
Book Value vs Market Value Analysis
This analysis compares Dicot Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.25x to 0.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.13 | €0.03 | x |
| 2022-12-31 | €0.02 | €0.03 | x |
| 2023-12-31 | €0.04 | €0.03 | x |
| 2024-12-31 | €0.06 | €0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dicot Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-51.67%) is above the historical average (-209.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -95.85% | 0.00% | 0.00x | 1.12x | €-30.01 Million |
| 2022 | -592.69% | 0.00% | 0.00x | 2.31x | €-32.29 Million |
| 2023 | -99.47% | 0.00% | 0.00x | 1.21x | €-48.60 Million |
| 2024 | -51.67% | 0.00% | 0.00x | 1.11x | €-68.86 Million |
Industry Comparison
This section compares Dicot Pharma AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dicot Pharma AB (KN0) | €106.30 Million | -95.85% | 0.11x | $47.64 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |